Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2008 Apr 14;6(5):575–583. doi: 10.1016/j.cgh.2008.02.035

Table 3.

Relative risk of EVR as a function of serum peginterferon concentration (per 1000 ng/ml) by treatment day adjusted for race.

Treatment Day Relative Risk (95% CI)a p-value
1 1.02 (1.0045, 1.03) 0.0073
2 1.01 (1.0055, 1.02) 0.0010
3 1.01 (0.99, 1.02) 0.4854
7 1.02 (1.0108, 1.04) 0.0003
14 1.01 (1.00, 1.02) 0.1541
28 1.01 (1.002, 1.02) 0.0159
56 1.01 (1.0085, 1.02) <.0001
84 1.01 (1.0035, 1.02) 0.0020
a

For every 1000 ng/ml increase in serum peginterferon concentration, EVR increased by 1-2%